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Circulating tumor cells (CTCs) are independent prognostic factors in the primary and metastatic breast cancer
patients and play crucial role in hematogenous tumor dissemination. The aim of this study was to correlate the
presence of CTCs in peripheral blood with the expression of proteins in tumor tissue that have a putative role in
regulation of cell growth and metastatic potential. This prospective study included 203 primary breast cancer
patients treated by definitive surgery. CTCs were detected by quantitative real-time PCR for the expression of
epithelial (CK19) or epithelial-to-mesenchymal transition–inducing transcription factor genes (TWIST1, SNAIL1,
SLUG, and ZEB1). Expression of APC, ADAM23, CXCL12, E-cadherin, RASSF1, SYK, TIMP3, BRMS1, and SOCS1
proteins in primary breast tumor tissue was evaluated by immunohistochemistry. CTCs with epithelial markers
were found in 17 (9.2%) patients. Their occurrence was associated with inhibition of SOCS1 expression (odds ratio
[OR] = 0.07; 95% confidence interval [CI], 0.03-0.13; P b .001). CTCs with positive epithelial-to-mesenchymal
transition markers were detected in 30 (15.8%) patients; however, no association with analyzed protein
expressions was found. Overall, CTCs were detected in 44 (22.9%) patients. Presence of any CTC marker was
significantly associated with positive CXCL12 expression (OR = 3.08; 95% CI, 1.15-8.26; P = .025) and lack of
SOCS1 expression (OR = 0.10; 95% CI, 0.04-0.25; P b .001) in patient’s tumor tissues. As both CXCL12 and(call code OPVaV-2011/4.2/07-SORO); and the Scientific Grant Agency, contract
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signaling cross talk between cytokine and chemokine responses could have an important role in hematogenous
dissemination of tumor cells in breast cancer.
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Breast cancer (BC) is one of the most frequently diagnosed cancers in
developed countries. The majority of cancer-related deaths occur as a
result of metastases, not the primary tumors from which these
malignancies arise [1]. During the metastatic process, cancer cells
acquire migratory and invasive capabilities that allow them to detach
from the primary tumor site, invade the surrounding tissues and
lymphatic or blood system, disseminate throughout the body, and
seed secondary tumors at distant sites [1,2].
Circulating tumor cells (CTCs) shed from the solid tumors into the
bloodstream are extremely rare cells surrounded with billions of blood
cells [3]. Growing evidence suggests that the CTC count increases
along with the tumor progression, especially with development of
distant metastases [4]. Higher level of the CTCs was associated with
unfavorable prognosis in various types of malignant tumors including
lung, breast, colorectal, and prostate cancer [5–8]. It has been shown
that CTCs can provide an early indication of patient’s response to
treatment beyond imaging studies [9]. The great potential that CTCs
hold for translational oncology depends on the level of molecular
characterization of the processes associated with hematological
dissemination of tumor cells [10].
To create metastasis, cells shed from the solid tumors have to undergo
the widespread reorganization of their cell biology, remodel cell-matrix
adhesion, diminish cell-cell contacts, and acquire invasive and migratory
skills. This reversible process known as the epithelial-to-mesenchymal
transition (EMT) [2,11] is a phenomenon that is currently highly
investigated in the field of oncology. The EMTprocess is characterized by
downregulation of gene expression of epithelial markers such as
cytokeratin and E-cadherin and upregulation of mesenchymal markers
such as vimentin and N-cadherin [12]. Cells undergoing EMT can also
acquire cancer stem cell (CSC) properties including the capacity for
self-renewal, redifferentiation, dormancy, active DNA repair, and drug
resistance [13].
Defects in immune response, chronic inflammation involving T
lymphocytes, and infiltration by Th2 and protumor-polarized innate
inflammatory cells were implicated in human tumorigenesis, including
metastatic spread [14,15]. The disruption of cancer cell dissemination
represents a powerful therapeutic strategy having the potential to prevent
advancedmetastatic diseases. Pharmacological targeting ofCTCs depends
primarily on the identification of suitablemolecular targets that are critical
for their occurrence, survival, and seeding.
In the current study, we hypothesized that aberrant expression of
proteins involved in the regulation of cell growth and inhibition of
invasivity and metastasizing could play a role in hematogenous
dissemination of tumor cells. Therefore, we examined the association
between expression of nine proteins: adenomatous polyposis coli (APC),
disintegrin and metalloprotease domain 23 (ADAM23), C-X-C motif
chemokine 12 (CXCL12), cadherin 1, type 1 (E-cadherin), RAS-associa-
tion domain family 1 (RASSF1), spleen tyrosine kinase (SYK), tissueinhibitor of the metalloproteinases 3 (TIMP3), breast cancer metastasis
suppressor 1 (BRMS1), and suppressor of cytokine signaling 1 (SOCS1),
assessed previously for the effect of DNA methylation on subsequent
protein expression in tumor tissues [16] and presence of CTCs in
peripheral blood of BC patients.
Materials and Methods
Patients
The samples for this translational study were collected according to
the Protocol TRU-SK 002 from 203 patients with stages I-III primary
BC who were undergoing definitive surgery. Each patient provided
peripheral blood for CTCs detection and formalin-fixed, paraffi-
n-embedded (FFPE) tumor tissue. Each patient was given a complete
diagnostic evaluation to exclude the presence of distant metastasis.
Patients with concurrent malignancy other than nonmelanoma skin
cancer in the previous 5 years were excluded as well. In all patients,
clinicopathologic data including age, tumor stage, histology, regional
lymph node involvement, hormone receptor (oestrogen and
progesterone), and HER2 status were recorded.
The study was approved by the Institutional Review Board of the
National Cancer Institute of Slovakia and was conducted between
March 2012 and September 2013. Healthy breast tissues from the
mammoplasties (N = 11) and peripheral blood samples of normal
age-matched women without BC (N = 60), who were recruited and
consented according to the Institutional Review Board–approved
protocol, were also analyzed. Written informed consent was obtained
from all individual participants included in the study.
Detection of CTCs in Peripheral Blood
Detailed description of the CTC detection method was published
recently by Cierna et al. [17]. Briefly, the protocol consists of three
major steps: CD45+ cell depletion, RNA extraction, and identifica-
tion of EMT-inducing factors and epithelial gene transcripts in
CD45-enriched subsets.
Peripheral blood mononuclear cells (PBMCs) were depleted from
blood samples using RosetteSep Human CD45 Depletion Cocktail
(StemCell Technologies, Vancouver, Canada) according to the
manufacturer’s instructions. RNA was extracted from CD45-depleted
cells with TRIzolVR LS Reagent (Invitrogen Corporation, Carlsbad,
CA). RNA was analyzed for expression of EMT-inducing transcrip-
tion factor gene transcripts (TWIST1, SNAIL1, SLUG, and ZEB1)
and epithelial antigen (CK19) by quantitative real-time (RT) PCR.
RT-PCRs were performed using TaqMan assays as described
previously [17]. Expressions of the genes of interest were calibrated
using the housekeeping gene GAPDH; delta-Ct method was used for
quantification of target genes. The highest expression levels of the
CK19 and EMT-inducing transcription factor gene transcripts
relative to that of GAPDH were 3.4 × 10−3, 2.0 × 10−4, 1 × 10−2,
Table 1. Clinical Characteristics
Variables N %
All 203 100.0
Age (y)
≤50 47 23.2
N50 156 76.8
T-stage
1 137 67.5
N1 66 32.5
N-stage
0 120 59.4
N1 82 40.6
Grade
1 and 2 125 62.8
3 74 37.2
Histology
IDC 175 86.2
Others 28 13.8
Hormone receptor status *
Negative 33 16.5
Positive 167 83.5
HER2 status
Negative 171 84.2
Amplified 32 15.8
Ki-67 †
Low 116 57.4
High 86 42.6
Tumor multifocality
Negative 180 89.1
Positive 22 10.9
Tumor subtypes
Luminal A like 80 40.2
Luminal B like HER2− 62 31.2
Luminal B like HER2+ 27 13.5
HER2+ nonluminal 5 2.5
Triple negative 25 12.6
CTC EP
Negative 168 90.8
Positive 17 9.2
CTC EMT
Negative 160 84.2
Positive 30 15.8
CTC any
Negative 148 77.1
Positive 44 22.9
* Negative for both or positive for either with cutoff 10%.
† Cutoff 20%.
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whereas SLUG transcripts were not detected in any of the samples
from healthy donors. These values were used as “cutoff” to determine
CTCs positivity. Patient samples with higher target gene expression than
those of healthy donors were considered as CTC positive. Positive gene
expression of any epithelial (CTCEP) and/ormesenchymal (CTCEMT)
gene transcripts was described as “CTC any.”
Immunohistochemistry
Immunohistochemical analyses were performed on FFPE tumor
and normal breast tissues. Immunohistochemistry was carried out for
expression of nine proteins using the general procedures described
previously [18]. As negative control, breast tissue was subjected to
staining procedure without reaction with the primary antibody.
Proteins analyzed in our study were associated with cell growth
regulation, cell adhesion, invasiveness, and metastasis (APC,
ADAM23, CXCL12, E-cadherin, RASSF1, SYK, TIMP3, BRMS1,
SOCS1). An ImmunoReactive Score (IRS) system, also known as the
German IRS, based on the proportion of positive cells and the
staining intensity of the nuclei or cytoplasm was applied [19]. The
scores from staining intensity and positive cells were multiplied,
giving quotients ranging between 0 and 12; protein expression was
stratified as negative (0) or positive with a staining intensity between 1
and 12.
Statistical Analysis
SPSS statistics 17.0 (SPSS Inc., Chicago, IL) was used for statistical
analyses of the data. Univariate analyses with χ2 or by the Fisher exact
test were performed to find association between protein expression
and CTC status followed by multivariate logistic regression analysis.
A logistic regression was used to determine the effect of the
independent categorical variables on presence of CTCs in peripheral
blood. This determination included the computation of the risk
estimate presented as estimated odds ratio (OR) and 95% confidence
interval (CI) for the OR. Each model included hormone receptor
status (negative for both or positive for either with cutoff of 10%),
HER-2 status (negative or overexpressed), tumor grade (1 and 2 vs 3),
tumor stage (stage T1 vs N T1), N stage (stage N0 vs N+), and
proteins significant in univariate analyses, respectively. Protein
expression was categorized as negative (IRS = 0) or positive (IRS ≥
1). A backward model selection was conducted, and the final fitted
model is presented. A P value b .05 was considered to indicate
statistical significance.
Results
In the present study, we investigated the associations between
expression of the nine above-mentioned proteins in tumor tissues of
primary BC patients and presence of CTCs in their peripheral blood.
Clinical characteristics of enrolled patients are shown in Table 1. The
age of patients ranged from 28 to 83 years, with a median age of 60
years; 76.8% of patients were older than 50 years. The majority of the
patients (86.2%) were diagnosed with invasive ductal carcinoma
(IDC), hormone receptor positivity (83.5%), node negativity
(59.4%), and low Ki-67 staining positivity (57.4%).
CTC Detection
Presence of CTC EP markers in peripheral blood was detected in
17 (9.2%), CTC EMT in 30 (15.8%), and CTC any in 44 (22.9%)
BC patients. Both epithelial and mesenchymal markers were foundin three (1.6%) patients, and coexpression of two mesenchymal
markers (SLUG and TWIST1) was detected in one (0.5%) of the
patients.
Relationship between Protein Expression in FFPE Tumor
Tissues and CTC in Peripheral Blood
The protein expression in FFPE tumor tissues differed for particular
genes.Whereas as many as half of the patients’ FFPE tumor tissues lacked
expression of TIMP3, APC, E-cadherin, and SYK (50%, 44.5%, 42.6%,
and 37.5%, respectively), expressions of SOCS1 and BRMS1 were
comparatively high (94% and 93.4% of samples, respectively). RASSF1,
ADAM23, andCXCL12 expressionwas inhibited in 29.8%, 24.5%, and
23.9% of the tumors. Examples of CXCL12 and SOCS1 expressions in
primary tumor samples are depicted in Figure 1. Status of protein
expression was compared with the presence of CTC EP, CTC EMT, or
both CTC markers (Table 2).
In the group of CTC EP–positive patients, 35.3% did not express
SOCS1 protein. However, among the CTC EP–negative patient
cohort, only 3% (P b .001) did not express SOCS1 protein (Table 2).
Multivariate analyses confirmed an inverse association between CTC
Figure 1. Protein expression patterns in primary breast tumors with positive and negative CXCL12 expression (a and b) and positive and
negative SOCS1 expression (c and d). Magnification 350× (B, C, D) or 400× (A).
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expression had a decreased risk of the occurrence of positive CTC EP
(OR = 0.07; 95% CI, 0.03-0.13; P b .001) (Table 3). In univariate
analysis, patients with positive CTC EP had more often inhibited
protein expression for E-cadherin and TIMP3 (64.7% vs 39.9%, P =
.050 and 75.0% vs 48.2%, P = .040, respectively), but these results
could not be confirmed by logistic regression.Table 2. Frequencies of Protein Expression in Particular CTC Groups
CTC EP CTC E
Protein Expression Negative N (%) Positive N (%) P Value Negativ
APC Negative 77 (46.7) 9 (52.9) .622 76 (48
Positive 88 (53.3) 8 (47.1) 82 (51
ADAM23 Negative 40 (24.2) 6 (35.3) .318 39 (24
Positive 125 (75.8) 11 (64.7) 118 (75
CXCL12 Negative 39 (23.5) 3 (17.6) .585 40 (25
Positive 127 (76.5) 14 (82.4) 119 (74
E-cadherin Negative 59 (39.9) 11 (64.7) .050 61 (42
Positive 89 (60.1) 6 (35.3) 83 (57
RASSF1 * Negative 20 (31.7) 3 (27.3) .767 23 (32
Positive 43 (68.3) 8 (72.7) 48 (67
SYK Negative 63 (38.0) 5 (29.4) .488 58 (36
Positive 103 (62.0) 12 (70.6) 100 (63
TIMP3 Negative 79 (48.2) 12 (75.0) .040 80 (51
Positive 85 (51.8) 4 (25.0) 76 (48
BRMS1 Negative 11 (6.7) 2 (11.8) .447 14 (9.
Positive 152 (93.3) 15 (88.2) 142 (91
SOCS1 Negative 5 (3.0) 6 (35.3) b .001 11 (7.
Positive 160 (97.0) 11 (64.7) 147 (93
Number of samples analyzed in the study was n = 203; only successfully analyzed samples were inclu
* For RASSF1, protein analyses were performed on 61 samples only because of the lack of material (tumorExpression of APC protein was significantly associated with
occurrence of CTC EMT markers using univariate analysis. Whereas
only 27.6% of patients had inhibited APC protein expression in the
CTC EMT–positive group, 48.1% of patients in CTC EMT–
negative group did not express this protein (P = .041) (Table 2).
However, multivariate analyses did not confirm this result, and any of
the analyzed proteins showed the significant effect on CTC EMTMT CTC Any
e N (%) Positive N (%) P Value Negative N (%) Positive N (%) P Value
.1) 8 (27.6) .041 71 (48.6) 15 (34.9) .112
.9) 21 (72.4) 75 (51.4) 28 (65.1)
.8) 8 (26.7) .833 34 (23.4) 13 (29.5) .412
.2) 22 (73.3) 111 (76.6) 31 (70.5)
.2) 3 (10.3) .081 40 (27.2) 5 (11.6) .035
.8) 26 (89.7) 107 (72.8) 38 (88.4)
.4) 11 (42.3) .996 53 (40.2) 21 (52.5) .167
.6) 15 (57.7) 79 (59.8) 19 (47.5)
.4) 1 (12.5) .246 20 (31.3) 4 (23.5) .535
.6) 7 (87.5) 44 (68.8) 13 (76.5)
.7) 12 (40.0) .732 54 (37.0) 16 (36.4) .940
.3) 18 (60.0) 92 (63.0) 28 (63.6)
.3) 13 (44.8) .523 71 (49.0) 23 (54.8) .508
.7) 16 (55.2) 74 (51.0) 19 (45.2)
0) 2 (6.9) .715 12 (8.3) 4 (9.3) .842
.0) 27 (93.1) 132 (91.7) 39 (90.7)
0) 1 (3.4) .478 5 (3.4) 7 (16.3) .002
.0) 28 (96.6) 141 (96.6) 36 (83.7)
ded in the table.
tissue).
Table 3. The Risk Estimation of the Analyzed Variables for Presence of CTCs in Peripheral Blood
of Patients Using Multivariate Logistic Regression
Circulating Tumor Cells Variables P Value OR 95% CI
CTC EP * Positive SOCS1 expression b .001 0.07 0.03-0.13
CTC EMT † Grade 3 .036 2.42 1.06-5.52
Positive APC expression .063 2.32 0.96-5.66
CTC any ‡ Positive CXCL12 expression .025 3.08 1.15-8.26
Positive SOCS1 expression b .001 0.10 0.04-0.25
* −2 Log likelihood = 78.55; R2 (Cox & Snell) = 0.58; R2 (Nagelkerke) = 0.78.
† −2 Log likelihood = 147.91; R2 (Cox & Snell) = 0.04; R2 (Nagelkerke) = 0.08.
‡ −2 Log likelihood = 180.65; R2 (Cox & Snell) = 0.33; R2 (Nagelkerke) = 0.43.
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the CTC EMT and APC protein expression (P = .063) (Table 3).
CXCL12 and SOCS1 protein expression differed significantly
according to the presence of any positive CTC marker. Inhibition of
SOCS1 protein expression was present in 16.3% of CTC positive versus
3.4%of CTC-negative patients (P = .002).On the contrary, inhibition of
CXCL12 expression was detected only in 11.6% of CTC-positive
compared with 27.2% of CTC-negative patients (P = .035). In
multivariate analysis, presence of any CTCs was significantly associated
with increased CXCL12 (OR = 3.08; 95% CI, 1.15-8.26; P = .025) and
inhibited SOCS1 expression (OR = 0.10; 95% CI, 0.04-0.25; P b .001)
in patients’ tumor tissues (Table 3).
Discussion
The occurrence of metastases within distant organs represents a
life-threatening event that is the main cause of death in BC and other
malignant diseases. The early spread of tumor cells in majority of cancers
may occur through either the lymphatic system and/or the blood vessels.
CTCs play a crucial role in the hematogenous dissemination and could
represent the independent prognostic factors for progression-free and
overall survival in primary and metastatic BC [20,21].
In the present study, we investigated the relationship between the
occurrence of CTCs in peripheral blood and expression of nine proteins
in the tumor tissues that have a putative role in regulation of cell growth
and metastatic potential. We found the relationship between expression
of cytokine signaling associated proteins, namely, CXCL12 and SOCS1,
and the presence of CTCs in peripheral blood of patients.
Chemokine CXCL12, known also as stromal cell–derived factor 1,
acts as a positive regulator of monocyte migration and a negative
regulator of monocyte adhesion. It activates the C-X-C chemokine
receptor CXCR4 and induces intracellular signaling through several
divergent pathways including chemotaxis, intracellular calcium flux,
cell survival, and proliferation [22]. CXCL12 expression was found to
be significantly higher in plasma of BC patients than in age-matched
female controls and had a significant correlation with tumor grade
and epithelial subtype [23] as well as with worse prognosis and
survival [24]. CXCL12 belongs to the group of chemokines that are
mostly secreted by leukocytes or stromal lineages such as endothelial
cells, mesenchymal fibroblasts, osteoblasts, and chondrocytes [25].
CXCL12 exhibits the peak level of the expression in organs
representing the first destinations of BC metastases. Stromal
CXCL12 expression might promote the survival of CXCR4-expres-
sing cells in the circulation and cell migration into extravascular
tissues, so-called homing or self-seeding, which belongs to major
drivers of tumor progression [21,26,27]. CXCL12 activation of the
specific intracellular pathways could lead to tumor progression either
directly, promoting cancer cell proliferation/survival, or indirectly,recruiting stromal cells to favor tumor relapse, dissemination, and
angiogenesis. The contribution of the stromal microenvironment to
the development of a wide variety of cancers has been shown
repeatedly [28]. Elevation of CXCL12 secretion by stromal
fibroblasts increases the probability of the tumor reinfiltration by
CTCs [29]. Recent studies also demonstrated that cancer cells
undergoing EMT acquire the CSC phenotype [13]. Tumor
self-seeding thus allows enrichment of primary neoplasm with highly
aggressive cell populations that may increase its metastatic potential
through the release of paracrine signals. It was shown that CSCs
isolated from the human glioblastoma expressed CXCR4 and released
CXCL12 in vitro [30]. The role of the CXCL12/CXCR4 signaling in
CSCs maintenance, dissemination, and consequent metastatic
colonization was reviewed in-depth by Cojoc et al. [31]. Although
the relationship between CXCL12 expression and CTCs has not been
established, our results are in accordance with previous findings
showing the association between unfavorable prognosis and elevation
of the CXCL12 expression. Pharmacologic inhibition of the
CXCL12/CXCR4 pathway decreased cancer cell proliferation,
motility, and invasion in multiple preclinical models both in vitro
and in vivo [31]. Neutralization of CXCR4 receptor was shown to
impair the formation of the lymph node metastases in vivo [32].
Several drugs that were already approved for treatment of hematological
malignancies give therapeutic opportunities for CXCR4 blockade also in
other types of cancer, including BC [33–35].
SOCS1 is a member of SOCS protein family that forms part of a
classical negative feedback system that regulates cytokine signal
transduction through the JAK/STAT pathway [36]. They control
onset and maintenance of allergic responses mediated by T-helper
type 2 cells, IL-6 signaling in vivo, and have significant roles in cancer
development and progression by tumor-associated inflammation and
suppression of antitumor immunity. SOCS1 contributes to the
regulation of proliferation, differentiation, apoptosis, and immune
surveillance in normal mammary epithelium. Abnormal expression of
SOCS1 in tumor cells has been detected in various human cancers,
including melanoma, chronic myeloid leukemia, and gastric and head
and neck carcinoma [37–40], where it was associated with
dysregulation of cytokine receptor and toll-like receptor signaling
and cell transformation. Silencing of the SOCS1 in BC was shown to
increase epithelial proliferation and cell survival in response to
cytokines and growth factors [41].
There is increasing evidence demonstrating that SOCS1 has
different functions depending on the origin of the tumor.
Methylation-dependent SOCS1 silencing was associated with
tumor growth in vitro and in vivo in Barrett adenocarcinoma [42].
On the other hand, the constitutive expression of SOCS1 was
demonstrated in peripheral blood of patients with chronic myeloid
leukaemia resistant to therapy and advanced human melanoma tumor
tissues [37,38]. For BC, increased SOCS1 expression in comparison
with healthy breast tissues was identified, but the number of analyzed
samples was rather low (3 for healthy breast tissue, 6 for in situ ductal
carcinomas, and 11 for IDC) [43]. Our results for healthy breast
tissues showed the variable SOCS1 protein expression. Inhibition of
SOCS1 expression was found in two healthy samples in contrast to
the other eight analyzed proteins, where only positive protein
expression was found [16]. Inconsistent results for different tumors
brought the opposite strategies of how to reduce or restore SOCS1
expression. The comprehensive understanding of the function and
the mechanisms of action of SOCS1 might facilitate its future
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target [41]. According to our best knowledge, the increased risk of
hematogenous dissemination in patients with inhibition of SOCS1
expression has not yet been reported. However, our results support
the recent findings that indicate the inverse relationship between
SOCS1 expression and epithelial proliferation and cell survival
mediated by JAK/STAT signaling [41].
Using univariate analyses, we found the moderate significance also
for TIMP3 expression and CTC EP and APC protein expression and
CTC EMT; however, we did not confirm these results by
multivariate analyses. The relatively small sample size and distinction
of CTC EP and CTC EMT subpopulations, which was discussed
previously [17], seem to be the major limitations of our study.
In conclusion, in this translational study, we observed, for the first
time, association between the presence of CTCs in peripheral blood of
BCpatients and aberrant expression of theCXCL12 and SOCS1proteins
in tumor tissues. These proteins are both involved in cytokine signaling
and immune response and could represent potential therapeutic targets to
gain control over tumor dissemination and self-seeding. Our data provide
support for the hypothesis that aberrant signaling cross talk between
cytokine and chemokine responses could have an important role in
hematogenous dissemination and tumor self-seeding. Although our
current knowledge of the role of the immune system in metastatic
processes remains limited, a deeper understanding of the interaction
between CTCs and their microenvironment is critical for the successful
control of tumor dissemination.
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